Alternate Name(s):
XOLAIR
Classification:
IgE neutralizing antibody (Anti-IgE)
Original Date:
March 2011
Indications:
- Treatment of moderate to severe persistent asthma in patients with a positive reaction to a perennial aeroallergen and who are inadequately controlled with inhaled steroids
Reconstitution and Stability:
- Refrigerate vials
- Reconstitue 202.5 mg vial with 1.4 mL Sterile Water for Injection to get 150 mg in 1.2 mL (125 mg/mL)
- Keeping vial upright swirl gently for 5 seconds every 5 minutes -DO NOT SHAKE
- May take greater than 20 minutes to dissolve completely
- Solution is clear or slightly opalescent
- After reconstitution protect from light
- Stable 8 hours refrigerated or 4 hours at room temperature- recommended to use within 4 hours following reconstitution
Compatibility:
- NO COMPATIBILITY information available for other drugs
Administration:
(For approved routes of administration by nursing personnel, refer to Policy for the Administration of Intravenous Medications.)
| SC |
YES - doses greater than 150 mg |
| IM | NO |
| IV Direct | NO |
| IV Intermittent Infusion | NO |
| IV Continuous Infusion | NO |
Dosage:
(For neonatal dosages, refer to Neonatal IV Drug Manual.)
Pediatric (greater than 12 years / Adult:
- 150 mg to 375 mg subcutaneous every 2 - 4 weeks
- dosing based on the serum total IgE before therapy is started and body weight
Potential hazards of parenteral administration:
- Hypersensitivity reactions - urticaria, dermatitis, pruritus, throat and/or tongue edema
- Dizziness, headache, fatigue, sinusitis
- Injection site reactions
- Viral infections, upper respiratory tract infection
Notes:
- Each vial contains 145 mg of sucrose (0.5 calories or 2.3 Joules)